Intro to COVID-19: Defining Emergency Use Authorization (EUA) Authorities

This session will address general regulatory requirements for bringing a medical product to market under emergency use authorities in the Federal Food, Drug, and Cosmetic Act.

Cathy L. Burgess, Partner, Alston & Bird LLP,  Member, FDLI Board of Directors

This session was recorded as part of FDLI’s virtual course, “COVID-19: Introduction to FDA’s Existing Legal Authorities and Emerging Issues” in August 2020.

 

Get Access

$99
  • +$100 for nonmembers
Legal issues regarding the response to COVID-19 is a rapidly evolving field. It is important to note the program recording date given that FDA guidance may have revised or been updated. For questions, please check the FDA website at:  https://www.fda.gov/home

Virtual Learning FAQ

On-demand webinar content is sent via email as soon as we are able to process and verify your order. This usually occurs within 1 business day.

 

On-demand content can be played back on most devices.

 

CLE credit is not currently available for pre-recorded sessions.

Related Content